Target intelligence / Profile preview

Bacillus Calmette-Guérin (live attenuated Mycobacterium bovis) (BCG)

Target
BCG
Molecular classification
Live-attenuated bacterial vaccine, Other (not a single protein, receptor, or genetic target; it is an entire bacterial organism)
01

Overview

Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis, originally developed by repeated subculture to reduce virulence[7]. It is the only vaccine approved worldwide for the prevention of tuberculosis, particularly severe forms such as infant meningitis and miliary TB[3][5]. BCG is also used as a first-line immunotherapeutic agent for non-muscle invasive bladder cancer, where it is instilled intravesically to activate local immune responses and reduce tumor recurrence[3][5]. BCG's protective efficacy in tuberculosis varies among substrains - resulting from historical genetic differences - and it can trigger robust innate and adaptive immune responses[1][4]. Intradermal or mucosal administration leads to local infection and immunological activation, mainly through recognition by antigen-presenting cells and stimulation of T-cell mediated immunity[4]. BCG is also exploited as a recombinant bacterial vector for novel vaccine development targeting other infectious or neoplastic diseases[3][2]. The main safety challenges include potential for disseminated infection in immunosuppressed individuals and variable efficacy depending on substrain and dosing[1][5]. The correct canonical target is the vaccine organism itself (Bacillus Calmette-Guérin), not a molecular target such as an enzyme, receptor, or transporter. If structured data is desired for drug targets at the molecular level, BCG should not be classified alongside genes/proteins but as a live attenuated vaccine organism.

Other names
Bacillus Calmette-GuérinBCGAttenuated Mycobacterium bovisMycobacterium bovis BCG
02

Mechanism of action

Induces strong cell-mediated immunity, predominantly T helper 1 (Th1) type response. Activation of innate immunity (macrophages, dendritic cells, monocytes via pattern recognition receptors like TLR2, TLR4, TLR9). Promotes production of cytokines (IL-2, IFN-γ, TNF-α, IL-12). Direct local immune activation and stimulation of antitumor responses in the bladder wall.

03

Biological functions

Immune response activation (cellular and humoral)Vaccine-induced protection against tuberculosisImmunotherapy (anti-tumor immune activation, particularly in bladder cancer)
04

Disease associations

Infection (tuberculosis)Cancer (non-muscle invasive bladder cancer)Other infectious diseases (as a bacterial vector for recombinant vaccines)
05

Safety considerations

Local inflammatory reactions (pain, swelling)Disseminated BCG infection in immunocompromised individualsSystemic adverse effects (rare): fever, sepsis, hypersensitivityOverattenuation may lead to reduced efficacy, while insufficient attenuation risks infection
06

Interacting drugs

Bacillus Calmette-Guérin (administered directly as a vaccine or as intravesical immunotherapy for bladder cancer)

1 more in the full profile.

07

Biomarkers

Interferon-γ and other Th1 cytokinesDelayed-type hypersensitivity (DTH) skin test response to mycobacterial antigensAntigen-specific memory T cell activation (e.g., Ag85A, ESAT6, CFP10—used in newer vaccine candidate monitoring)

Beyond the preview

Go deeper on Bacillus Calmette-Guérin (live attenuated Mycobacterium bovis) (BCG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacillus Calmette-Guérin (live attenuated Mycobacterium bovis) (BCG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call